ADXS - Advaxis, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
1.71
-0.08 (-4.47%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close1.79
Open1.79
Bid1.45 x 1200
Ask2.11 x 4000
Day's range1.68 - 1.79
52-week range1.51 - 7.45
Volume909,199
Avg. volume585,050
Market cap89.983M
Beta3.71
PE ratio (TTM)N/A
EPS (TTM)-2.08
Earnings date10 Sep 2018 - 14 Sep 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.67
Trade prices are not sourced from all markets
  • Business Wire9 days ago

    Advaxis Announces Dosing of First Patient with ADXS-NEO, an Investigational Customized Immunotherapy Approach Targeting Personal Neoantigens

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced it has commenced a Phase 1 trial with the dosing of the first patient with ADXS-NEO, an investigational personalized immunotherapy approach targeting personal neoantigens found by sequencing a patient’s own cancer cells. ADXS-NEO is being evaluated in an open-label, dose-escalation, multicenter Phase 1 clinical trial in the United States. The study is open to patients with metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer.

  • Associated Press13 days ago

    Advaxis: Fiscal 2Q Earnings Snapshot

    On a per-share basis, the Princeton, New Jersey-based company said it had a loss of 27 cents. The biotechnology company posted revenue of $1.7 million in the period. The company's shares closed at $1.71. ...

  • Business Wire13 days ago

    Advaxis Announces Prioritization of Product Portfolio and Reports Fiscal 2018 Second Quarter Financial Results

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced a new prioritization of its product portfolio, as well as financial results and business highlights for the three months ended April 30, 2018. The product portfolio review was conducted under the leadership of recently appointed President and CEO Ken Berlin, along with the full Advaxis executive team including recently named Chief Medical Officer Andres Gutierrez, M.D., Ph.D. The process reflects a commitment to allocate capital to programs that meet three criteria: (i) commercially attractive applications for the company’s Lm technology platform, (ii) the opportunity for the Lm platform to meaningfully impact cancer care, and (iii) a rapid and cost-effective route to generate clinical and immunological response data to demonstrate proof of concept.

  • Business Wire14 days ago

    Advaxis Appoints Molly Henderson as Chief Financial Officer

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced the appointment of Molly Henderson as Executive Vice President and Chief Financial Officer, effective June 6, 2018. Ms. Henderson joins Advaxis from Cedar Cliff, LLC, where she served as a financial and business consultant to high-growth entrepreneurial companies. Previously she was Chief Financial Officer at Iovance Biotherapeutics, Inc. (formerly Lion Biotechnologies, Inc.) (IOVA), an immuno-oncology company where she was responsible for all financial, SEC reporting, legal, governance, human resources and IT-related functions, and raised $100 million in equity capital.

  • Business Wire19 days ago

    Data Highlighting Advaxis’ ADXS-PSA Presented at ASCO Annual Meeting

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced preliminary data from the ongoing metastatic, castration resistant prostate cancer (mCRPC) Phase 1/2 KEYNOTE-046 study, conducted in conjunction with Merck (known as MSD outside the United States and Canada) evaluating ADXS-PSA, Advaxis’s Listeria monocytogenes (Lm)-based immunotherapy, alone and in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy.

  • Business Wire20 days ago

    Advaxis to Host Business Update and Second Quarter 2018 Financial Results Conference Call on June 7, 2018

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announced today the upcoming release of financial results for the six months ended April 30, 2018, to take place on Thursday, June 7, 2018. Advaxis’ senior management will host a conference call to review its financial results and provide a business update. The conference call and live audio webcast will begin at 11:00 a.m. Eastern time on Thursday, June 7, 2018.

  • Business Wirelast month

    Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent

    Advaxis, Inc. (ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, provides an update on recently presented preclinical data demonstrating the anti-cancer potential of their Lm vector that presents tumor neoantigens, and is being evaluated in the ADXS-NEO program. ADXS-NEO is derived from the Company’s proprietary Lm Technology and is being developed in partnership with Amgen. These preclinical findings were discussed in poster presentations at the recent American Association for Cancer Research (AACR) Annual Meeting.

  • Advaxis Announces Executive Leadership Changes
    Business Wire2 months ago

    Advaxis Announces Executive Leadership Changes

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that Kenneth A.

  • Business Wire2 months ago

    Preclinical Data Highlighting ADXS-Hot as Immunotherapy with Potential to Target Hotspot Cancer Mutations across Multiple Cancer Types Presented in Poster Discussion at The AACR Annual Meeting

     Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces the presentation of ADXS-HOT preclinical data in a poster discussion entitled “Targeting Shared Hotspot Cancer Mutations with a Listeria monocytogenes Immunotherapy Induce Potent Anti-Tumor Immunity” at the American Association for Cancer Research Annual ...

  • Business Wire3 months ago

    Data Highlighting Advaxis’ ADXS-PSA Accepted as Poster Presentation at the American Society of Clinical Oncology Annual Meeting

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that The American Society of Clinical Oncology has accepted the abstract titled “ADXS-PSA plus pembrolizumab in metastatic castration-resistant prostate cancer ” for a poster discussion at their annual meeting to be held June 1-5, 2018 in Chicago.

  • Business Wire3 months ago

    Advaxis Announces Four Poster Presentations Highlighting Lm-based Antigen Delivery Technology at AACR 2018

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced that results from multiple preclinical studies of its Lm-based antigen delivery technology will be presented at the American Association for Cancer Research Annual Meeting 2018 , April 14-18, 2018 in Chicago.

  • Business Wire3 months ago

    Advaxis to Present at Upcoming March Conferences

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies,

  • Associated Press3 months ago

    Advaxis reports 1Q loss

    The Princeton, New Jersey-based company said it had a loss of 49 cents per share. The biotechnology company posted revenue of $2.1 million in the period. In the final minutes of trading on Monday, the ...

  • Business Wire3 months ago

    Advaxis Reports Fiscal 2018 First Quarter Financial Results and Announces Clinical Hold in Axalimogene Filolisbac Phase 1/2 Combination Study with AstraZeneca’s IMFINZI® (Durvalumab)

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces financial results for the three months ended January 31, 2018 and provides a business update.

  • Business Wire3 months ago

    Advaxis to Host Business Update and First Quarter 2018 Financial Results Conference Call on March 12, 2018

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the upcoming release of financial results for the three months ended January 31, 2018, to take place on Monday, March 12, 2018.

  • Business Wire4 months ago

    Advaxis Prices $20.0 Million Public Offering of Common Stock

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, announced today the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $2.00 per share.

  • Business Wire4 months ago

    Advaxis Announces Proposed Public Offering of Common Stock

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

  • Business Wire4 months ago

    Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization Application to the European Medicines Agency for the company’s lead Lm Technology product candidate, axalimogene filolisbac, for the treatment of adult women who progress beyond first-line therapy of persistent, ...

  • Business Wire4 months ago

    Advaxis Submits Conditional Marketing Authorization Application for Axalimogene Filolisbac for the Second-Line Treatment of Metastatic Cervical Cancer in European Union

    Advaxis, Inc. (NASDAQ:ADXS), a late-stage biotechnology company focused on the discovery, development and commercialization of cancer immunotherapies has submitted a conditional Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for the company’s lead Lm Technology product candidate, axalimogene filolisbac, for the treatment of adult women who progress beyond first-line therapy of persistent, recurrent or metastatic carcinoma of the cervix (PRmCC). “The submission of the MAA represents a significant regulatory milestone for Advaxis and the ongoing development of our Lm Technology Platform,” stated Anthony Lombardo, interim Chief Executive Officer of Advaxis.

  • Business Wire4 months ago

    Advaxis Announces Publication of Phase 2 Results Evaluating Axalimogene Filolisbac for the Treatment of Recurrent Metastatic Cervical Cancer in the International Journal of Gynecological Cancer

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that data from an earlier Phase 2 clinical study of axalimogene filolisbac as a treatment for persistent or recurrent metastatic carcinoma of the cervix was accepted for publication in the May edition of peer-reviewed International Journal of Gynecological ...

  • Business Wire5 months ago

    Data Highlighting Advaxis’ Antigen Delivery Platform Accepted for Multiple Presentations at 2018 Keystone Symposia Conference on Cancer Immunotherapies

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that three abstracts highlighting the Company’s Listeria-based immunotherapy in combination with antibody-based immunotherapies have been accepted for poster presentation at the upcoming 2018 Keystone Symposia on Cancer Immunotherapies: Combinations taking ...

  • Business Wire5 months ago

    Advaxis’ Immunotherapy in Combination with Chemoradiation Highlighted as Potential Treatment for Anal Cancer in International Journal of Radiation Oncology

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announces that data from the investigator-initiated study evaluating the Company’s proprietary Lm-based antigen delivery product, axalimogene filolisbac , in combination with chemoradiation as a treatment for high-risk, locally advanced anal cancer were published ...

  • Business Wire6 months ago

    Advaxis Reports Fiscal Year 2017 Financial Results and Provides a Business Update

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today provides a business update and announces its financial results for the fiscal year ended October 31, 2017.

  • Business Wire6 months ago

    Advaxis to Host Business Update and Fiscal Year End 2017 Financial Results Conference Call on December 21, 2017

    Advaxis, Inc.  , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, announces that the Company will release financial results for the fiscal year ended October 31, 2017 on Wednesday, December 20, 2017.

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes